Development of spexin-based human galanin receptor type II-specific agonists with increased stability in serum and anxiolytic effect in mice

Arfaxad Reyes-Alcaraz, Yoo Na Lee, Gi Hoon Son, Nam Hoon Kim, Dong Kyu Kim, Seongsik Yun, Dong-Hun Kim, Jong-Ik Hwang, Jae Young Seong

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The novel neuropeptide spexin (SPX) was discovered to activate galanin receptor 2 (GALR2) and 3 (GALR3) but not galanin receptor 1 (GALR1). Although GALR2 is known to display a function, particularly in anxiety, depression, and appetite regulation, the further determination of its function would benefit from a more stable and selective agonist that acts only at GALR2. In the present study, we developed a GALR2-specific agonist with increased stability in serum. As galanin (GAL) showed a low affinity to GALR3, the residues in SPX were replaced with those in GAL, revealing that particular mutations such as Gln5 → Asn, Met7 → Ala, Lys11 → Phe, and Ala13 → Pro significantly decreased potencies toward GALR3 but not toward GALR2. Quadruple (Qu) mutation of these residues still retained potency to GALR2 but totally abolished the potency to both GALR3 and GALR1. The first amino acid modifications or D-Asn1 substitution significantly increased the stability when they are incubated in 100% fetal bovine serum. Intracerebroventricular administration of the mutant peptide with D-Asn1 and quadruple substitution (dN1-Qu) exhibited an anxiolytic effect in mice. Taken together, the GALR2-specific agonist with increased stability can greatly help delineation of GALR2-mediated functions and be very useful for treatments of anxiety disorder.

Original languageEnglish
Article number21453
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 2016 Feb 24

Fingerprint

Receptor, Galanin, Type 2
Galanin Receptors
Anti-Anxiety Agents
Serum
Receptor, Galanin, Type 1
Galanin
Receptor, Galanin, Type 3
Appetite Regulation
Mutation
Anxiety Disorders
Neuropeptides

ASJC Scopus subject areas

  • General

Cite this

@article{19a9d525a39c46c7b999af28e004a97b,
title = "Development of spexin-based human galanin receptor type II-specific agonists with increased stability in serum and anxiolytic effect in mice",
abstract = "The novel neuropeptide spexin (SPX) was discovered to activate galanin receptor 2 (GALR2) and 3 (GALR3) but not galanin receptor 1 (GALR1). Although GALR2 is known to display a function, particularly in anxiety, depression, and appetite regulation, the further determination of its function would benefit from a more stable and selective agonist that acts only at GALR2. In the present study, we developed a GALR2-specific agonist with increased stability in serum. As galanin (GAL) showed a low affinity to GALR3, the residues in SPX were replaced with those in GAL, revealing that particular mutations such as Gln5 → Asn, Met7 → Ala, Lys11 → Phe, and Ala13 → Pro significantly decreased potencies toward GALR3 but not toward GALR2. Quadruple (Qu) mutation of these residues still retained potency to GALR2 but totally abolished the potency to both GALR3 and GALR1. The first amino acid modifications or D-Asn1 substitution significantly increased the stability when they are incubated in 100{\%} fetal bovine serum. Intracerebroventricular administration of the mutant peptide with D-Asn1 and quadruple substitution (dN1-Qu) exhibited an anxiolytic effect in mice. Taken together, the GALR2-specific agonist with increased stability can greatly help delineation of GALR2-mediated functions and be very useful for treatments of anxiety disorder.",
author = "Arfaxad Reyes-Alcaraz and Lee, {Yoo Na} and Son, {Gi Hoon} and Kim, {Nam Hoon} and Kim, {Dong Kyu} and Seongsik Yun and Dong-Hun Kim and Jong-Ik Hwang and Seong, {Jae Young}",
year = "2016",
month = "2",
day = "24",
doi = "10.1038/srep21453",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Development of spexin-based human galanin receptor type II-specific agonists with increased stability in serum and anxiolytic effect in mice

AU - Reyes-Alcaraz, Arfaxad

AU - Lee, Yoo Na

AU - Son, Gi Hoon

AU - Kim, Nam Hoon

AU - Kim, Dong Kyu

AU - Yun, Seongsik

AU - Kim, Dong-Hun

AU - Hwang, Jong-Ik

AU - Seong, Jae Young

PY - 2016/2/24

Y1 - 2016/2/24

N2 - The novel neuropeptide spexin (SPX) was discovered to activate galanin receptor 2 (GALR2) and 3 (GALR3) but not galanin receptor 1 (GALR1). Although GALR2 is known to display a function, particularly in anxiety, depression, and appetite regulation, the further determination of its function would benefit from a more stable and selective agonist that acts only at GALR2. In the present study, we developed a GALR2-specific agonist with increased stability in serum. As galanin (GAL) showed a low affinity to GALR3, the residues in SPX were replaced with those in GAL, revealing that particular mutations such as Gln5 → Asn, Met7 → Ala, Lys11 → Phe, and Ala13 → Pro significantly decreased potencies toward GALR3 but not toward GALR2. Quadruple (Qu) mutation of these residues still retained potency to GALR2 but totally abolished the potency to both GALR3 and GALR1. The first amino acid modifications or D-Asn1 substitution significantly increased the stability when they are incubated in 100% fetal bovine serum. Intracerebroventricular administration of the mutant peptide with D-Asn1 and quadruple substitution (dN1-Qu) exhibited an anxiolytic effect in mice. Taken together, the GALR2-specific agonist with increased stability can greatly help delineation of GALR2-mediated functions and be very useful for treatments of anxiety disorder.

AB - The novel neuropeptide spexin (SPX) was discovered to activate galanin receptor 2 (GALR2) and 3 (GALR3) but not galanin receptor 1 (GALR1). Although GALR2 is known to display a function, particularly in anxiety, depression, and appetite regulation, the further determination of its function would benefit from a more stable and selective agonist that acts only at GALR2. In the present study, we developed a GALR2-specific agonist with increased stability in serum. As galanin (GAL) showed a low affinity to GALR3, the residues in SPX were replaced with those in GAL, revealing that particular mutations such as Gln5 → Asn, Met7 → Ala, Lys11 → Phe, and Ala13 → Pro significantly decreased potencies toward GALR3 but not toward GALR2. Quadruple (Qu) mutation of these residues still retained potency to GALR2 but totally abolished the potency to both GALR3 and GALR1. The first amino acid modifications or D-Asn1 substitution significantly increased the stability when they are incubated in 100% fetal bovine serum. Intracerebroventricular administration of the mutant peptide with D-Asn1 and quadruple substitution (dN1-Qu) exhibited an anxiolytic effect in mice. Taken together, the GALR2-specific agonist with increased stability can greatly help delineation of GALR2-mediated functions and be very useful for treatments of anxiety disorder.

UR - http://www.scopus.com/inward/record.url?scp=84959387174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959387174&partnerID=8YFLogxK

U2 - 10.1038/srep21453

DO - 10.1038/srep21453

M3 - Article

C2 - 26907960

AN - SCOPUS:84959387174

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 21453

ER -